Coeptis director acquires 8,950 COEP shares total

Coeptis Therapeutics Holdings, Inc. director Tara DeSilva reported acquiring additional common stock on February 11, 2026.

Accepted by SEC EDGAR 02/13/2026 - 05:00 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Coeptis Therapeutics Holdings, Inc. director Tara DeSilva reported acquiring additional common stock on February 11, 2026. She obtained 5,700 shares through the exercise of stock options at an exercise price of $10.56 per share, and separately received a grant of 3,250 restricted shares in connection with an option exchange program where underwater options were surrendered. Following these transactions, she directly holds 8,950 shares of Coeptis Therapeutics common stock.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider DeSilva Tara

Role Director

Type	Security	Shares	Price	Value
Exercise	Common stock	5,700	$10.56	$60K
Grant/Award	Common Stock	3,250	$0.00	$0.00

Holdings After Transaction: Common Stock — 8,950 shares (Direct)

Footnotes (2)

1. F1. Represents the exercise price of shares purchased upon exercise of stock options.
2. F2. Represents a grant of restricted stock issued in connection with an option exchange program where the Reporting Person surrendered underwater options in exchange for a grant of restricted stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Tara DeSilva report at Coeptis Therapeutics (COEP)?

Tara DeSilva reported acquiring Coeptis Therapeutics common stock on February 11, 2026. She exercised stock options for 5,700 shares and received a grant of 3,250 restricted shares through an option exchange program, increasing her direct ownership stake.

How many Coeptis Therapeutics (COEP) shares did Tara DeSilva acquire via option exercise?

She acquired 5,700 shares of Coeptis Therapeutics common stock through the exercise of stock options. The option exercise price was $10.56 per share, as disclosed, and the transaction is classified as an exercise or conversion of a derivative security.

What was the restricted stock grant reported by Tara DeSilva for COEP?

Tara DeSilva received a grant of 3,250 shares of restricted Coeptis Therapeutics common stock. The grant occurred as part of an option exchange program in which she surrendered underwater stock options in exchange for newly issued restricted shares.

What is Tara DeSilva’s total Coeptis Therapeutics share ownership after these transactions?

After the reported transactions, Tara DeSilva directly owns 8,950 shares of Coeptis Therapeutics common stock. This total reflects both the 5,700 shares from her option exercise and the 3,250 restricted shares granted in the option exchange program.

On what date did the Coeptis Therapeutics (COEP) insider transactions occur?

Both reported insider transactions occurred on February 11, 2026. That date covers the exercise of stock options for 5,700 shares and the related grant of 3,250 restricted shares issued under the company’s option exchange program.

What do the transaction codes M and A mean in Tara DeSilva’s COEP Form 4?

Code M reflects the exercise or conversion of a derivative security, in this case stock options exercised for 5,700 shares. Code A indicates a grant, award, or other acquisition, covering the 3,250 restricted shares issued in the option exchange program.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DeSilva Tara

(Last) (First) (Middle)

105 BRADFORD ROAD, SUITE 420

(Street)

WEXFORD PA 15090

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Coeptis Therapeutics Holdings, Inc. [ COEP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common stock	02/11/2026		M		5,700	A	$10.56(1)	8,950	D
Common Stock	02/11/2026		A		3,250	A	$0(2)	8,950	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the exercise price of shares purchased upon exercise of stock options.

2. Represents a grant of restricted stock issued in connection with an option exchange program where the Reporting Person surrendered underwater options in exchange for a grant of restricted stock.

	/s/ Tara DeSilva	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.